SAM
TGTX icon

Silvercrest Asset Management’s TG Therapeutics TGTX Stock Holding History

Silvercrest Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,000
Closed -$111K – 562
2017
Q2 		$111K Buy
+11,000
New +$123K ﹤0.01% 528

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Silvercrest Asset Management's TGTX Position: Q3 2017 in Review

Silvercrest Asset Management sold out of TG Therapeutics (TGTX) in Q3 2017, closing a stake of 11,000 shares — an estimated $111K sold.

Silvercrest Asset Management first reported a position in TGTX in Q2 2017 and held it in 1 quarter. The position peaked at $111K in Q2 2017. 101 funds tracked by Wall St. Rank hold TGTX as of Q3 2017.

  • Silvercrest Asset Management reported no remaining TG Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Silvercrest Asset Management sold 11,000 TG Therapeutics shares in Q3 2017, an estimated $111K.
  • Silvercrest Asset Management first reported a position in TG Therapeutics in Q2 2017 and held it in 1 quarter.
  • Silvercrest Asset Management's TG Therapeutics position peaked at $111K in Q2 2017.
  • 101 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2017.

Based on Silvercrest Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.